Latest Conference Articles

Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer

The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma

Dr. Katherine Virgo from the American Cancer Society Discusses Survivorship Care Training & Policies

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib

Apostolia M. Tsimberidou, MD, PhD, from MD Anderson Cancer Center discusses improving cancer care.

Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores

Taking a page from breast cancer treatment, clinicians managing lung cancer patients can now detect mutations that drive the development of lung cancer

Metastatic breast cancer patients with demonstrated disease progression after taxane therapy face an uphill battle in fighting their disease.

Prostate cancer research lacks surrogate biomarkers for survival that could hasten the study and approval of new medications.

Radiation therapy directed to the regional lymph nodes of women with early-stage breast cancer reduced distant disease recurrence

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

High doses of methotrexate increases EFS for children and young adults

Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes

Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial

Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances

Oncology specialists, biopharmaceutical analysts and investors all await the latest research news from the upcoming ASCO annual meeting

A genetic analysis resulted in the discovery of the first predictive biomarker for taxane-induced peripheral neuropathy

Cabozantinib (XL184), an investigational oral tyrosine kinase inhibitor, demonstrated antitumor activity in multiple types of advanced solid tumors.

The risk of dying from ovarian cancer was not reduced when women received CA-125 blood testing and transvaginal ultrasound

A large-scale study of HPV testing and Pap smear for cervical cancer screening confirms that women can safely extend screening intervals from 1 to 3 years.

Prostate-specific antigen (PSA) levels can accurately predict the risk of developing metastasis or death from prostate cancer up to 30 years later

A prospective study analyzed the risk of contracting common cancers based on baseline self-reporting data on smoking, alcohol use, and physical activity

ASCO 2011, June 3-7, 2011 McCormick Place, Chicago, IL

Donna Berry on the Distinguished Researcher Award and Her Advice to Researchers

Carlton Brown Describes Key Messages of the ONS Congress

Keynote Presenter Cancer Survivor Charlie Lustman Lives to Tell His Story

Susan Moore Oncology Nurse Practitioner/Consultant, MCG Oncology on Adapting a Practice for Use of Oral Oncolytics

Oral oncolytics are frequently used in cancer treatment and they make up approximately 25% of the medications in the oncology pipeline

Honorary Mistress of Ceremonies Cynthia Nixon kicked off the ONS 36th Annual Congress Cure magazine Extraordinary Healer Award with a rousing tribute